NASDAQ$RPTX
Repare Therapeutics Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Reported financial results for the second quarter ended June 30, 2022.
Repare Therapeutics reported revenue of $0.7 million and a net loss of $38.1 million for the second quarter of 2022. They also entered into a worldwide license and collaboration agreement with Roche for camonsertib, receiving a $125 million upfront payment in July 2022.
- Signed worldwide license and collaboration agreement with Roche for camonsertib.
- Received a $125 million upfront payment from Roche in July 2022.
- Advanced RP-6306, a first-in-class, oral PKMYT1 inhibitor as a monotherapy and in combinations.
- Initiated IND-enabling studies for the polymerase theta inhibitor, now designated as RP-2119.
Headline financials
Revenue & EPS history
Repare Therapeutics · Revenue · Quarterly
$679K
Forward guidance
Repare Therapeutics expects to continue the clinical and preclinical development of their pipeline, including RP-6306 and RP-2119. They also anticipate potential milestone payments from the Roche collaboration and further development of product candidates using their SNIPRx platform technology.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 7 quarterly earnings reports
+0.7%
Avg return
Earnings day
+3.3%
Avg return
5 days after
-0.1%
Avg return
30 days after
55%
12 / 22 earnings
Positive
+19.7%
Q2 2023
Best reaction
-13.5%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | -2.4% | +27.5% | +26.3% | |
| Q2 2025 | +0.0% | +3.3% | +11.2% | |
| Q1 2025 | +3.8% | +0.0% | +9.1% | |
| Q4 2024 | -1.7% | +0.9% | -9.4% | |
| Q3 2024 | -0.6% | -4.4% | -13.5% | |
| Q2 2024 | -4.8% | -8.3% | -11.9% | |
| Q1 2024 | +11.5% | +7.7% | +17.4% | |
| Q4 2023 | +4.4% | -0.6% | -29.9% | |
| Q3 2023 | -6.6% | — | — | |
| Q2 2023 | +19.7% | — | — | |
| Q1 2023 | +1.5% | — | — | |
| Q4 2022 | +2.0% | — | — | |
| Q3 2022 | +7.7% | — | — | |
| Q2 2022 | +0.2% | — | — | |
| Q1 2022 | -9.2% | — | — | |
| Q4 2021 | +0.4% | — | — | |
| Q3 2021 | +2.2% | — | — | |
| Q2 2021 | -0.2% | — | — | |
| Q1 2021 | +0.5% | — | — | |
| Q4 2020 | -13.5% | — | — | |
| Q3 2020 | -2.3% | — | — | |
| Q2 2020 | +2.6% | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro